{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:08:18Z","timestamp":1777018098410,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T00:00:00Z","timestamp":1375920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00345-013-1144-x","type":"journal-article","created":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T09:08:24Z","timestamp":1375866504000},"page":"661-667","source":"Crossref","is-referenced-by-count":6,"title":["Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma"],"prefix":"10.1007","volume":"32","author":[{"given":"Domenico","family":"Prezioso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ruffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Illiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"key":"1144_CR1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"1144_CR2","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV (1941) Studies on prostate cancer I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293\u2013297","journal-title":"Cancer Res"},{"key":"1144_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209","journal-title":"Arch Surg"},{"issue":"Suppl 1","key":"1144_CR4","first-page":"53","volume":"15","author":"J Geller","year":"1988","unstructured":"Geller J, Albert J, Vik A (1988) Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 15(Suppl 1):53","journal-title":"Semin Oncol"},{"issue":"382","key":"1144_CR5","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/jco.2004.22.14_suppl.4504","volume":"23","author":"M Bolla","year":"2004","unstructured":"Bolla M et al (2004) Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Proc Am Soc Clin Oncol 23(382):4504","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1144_CR6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-5347(05)64058-X","volume":"169","author":"GD Grossfeld","year":"2003","unstructured":"Grossfeld GD et al (2003) Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157\u2013163","journal-title":"J Urol"},{"key":"1144_CR7","first-page":"1444","volume":"9","author":"C Catton","year":"2002","unstructured":"Catton C et al (2002) Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol 9:1444\u20131452","journal-title":"Can J Urol"},{"key":"1144_CR8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0090-4295(02)01997-0","volume":"60","author":"MB Gretzer","year":"2002","unstructured":"Gretzer MB et al (2002) Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. Urology 60:1034\u20131039","journal-title":"Urology"},{"key":"1144_CR9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","volume":"167","author":"GW Hull","year":"2002","unstructured":"Hull GW et al (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528\u2013534","journal-title":"J Urol"},{"key":"1144_CR10","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"1144_CR11","unstructured":"National Institute for Health and Clinical Excellence (2002) Guidance on cancer services\u2014improving outcomes in urological cancers: the manual, September"},{"key":"1144_CR12","volume-title":"Oxford Handbook of Clinical Medicine","year":"1998","unstructured":"Hope RA, Longmore JM, McManus SK, Wood-Allum C (eds) (1998) Oxford Handbook of Clinical Medicine, 4th edn. Oxford University Press, Oxford","edition":"4"},{"key":"1144_CR13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0094-0143(02)00187-8","volume":"30","author":"DF Penson","year":"2003","unstructured":"Penson DF, Litwin MS (2003) The physical burden of prostate cancer. Urol Clin North Am 30:305\u2013313","journal-title":"Urol Clin North Am"},{"key":"1144_CR14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/pon.797","volume":"13","author":"B Rosenfeld","year":"2004","unstructured":"Rosenfeld B et al (2004) Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology 13:800\u2013807","journal-title":"Psychooncology"},{"key":"1144_CR15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pon.702","volume":"12","author":"K Lintz","year":"2003","unstructured":"Lintz K et al (2003) Prostate cancer patients\u2019 support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology 12:769\u2013783","journal-title":"Psychooncology"},{"key":"1144_CR16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11864-004-0027-1","volume":"5","author":"MR Smith","year":"2004","unstructured":"Smith MR (2004) Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol 5:367\u2013375","journal-title":"Curr Treat Options Oncol"},{"issue":"Suppl 6A","key":"1144_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0090-4295(99)00448-3","volume":"54","author":"JA Smith Jr","year":"1999","unstructured":"Smith JA Jr, Soloway MS, Young MJ (1999) Complications of advanced prostate cancer. Urology 54(Suppl 6A):8\u201314","journal-title":"Urology"},{"key":"1144_CR18","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/01.ju.0000053243.87457.60","volume":"169","author":"PM Ullrich","year":"2003","unstructured":"Ullrich PM et al (2003) Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol 169:1449\u20131452","journal-title":"J Urol"},{"key":"1144_CR19","volume-title":"Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine","author":"DB Petitti","year":"2000","unstructured":"Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, Oxford","edition":"2"},{"key":"1144_CR20","first-page":"400","volume":"48","author":"B Montreuil","year":"2005","unstructured":"Montreuil B, Bendavid Y, Brophy J (2005) What is so odd about odds? Can J Surg 48:400\u2013402","journal-title":"Can J Surg"},{"key":"1144_CR21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1144_CR22","unstructured":"StatsDirect Ltd (2002) Accessed January 2007"},{"key":"1144_CR23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.1950.02910500019005","volume":"143","author":"RM Nesbit","year":"1950","unstructured":"Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J Am Med Assoc 143:1317","journal-title":"J Am Med Assoc"},{"key":"1144_CR24","first-page":"1011","volume":"124","author":"Veterans Administration Cooperative Urological Research Group, authors","year":"1967","unstructured":"Veterans Administration Cooperative Urological Research Group, authors (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011","journal-title":"Surg Gynecol Obstet"},{"key":"1144_CR25","first-page":"7","volume":"359","author":"MM Christensen","year":"1990","unstructured":"Christensen MM, Aagaard J, Madsen PO (1990) Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur). Prog Clin Biol Res 359:7\u201314","journal-title":"Prog Clin Biol Res"},{"key":"1144_CR26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","volume":"79","author":"The Medical Research Council Prostate Cancer Working Party Investigators Group","year":"1997","unstructured":"The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79:235\u2013246","journal-title":"Br J Urol"},{"key":"1144_CR27","unstructured":"Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group (2000) Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 86(Suppl 3):220, MP6.1.07"},{"key":"1144_CR28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.ju.0000135742.13171.d2","volume":"172","author":"FH Schroder","year":"2004","unstructured":"Schroder FH et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846\u2014a phase III study. J Urol 172:923\u2013927","journal-title":"J Urol"},{"key":"1144_CR29","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","volume":"172","author":"MP Wirth","year":"2004","unstructured":"Wirth MP et al (2004) Bicalutamide 150\u00a0mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865\u20131870","journal-title":"J Urol"},{"key":"1144_CR30","doi-asserted-by":"crossref","unstructured":"Studer UE et al. (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 24(12):1868\u20131876","DOI":"10.1200\/JCO.2005.04.7423"},{"key":"1144_CR31","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/01.ju.0000141712.79986.77","volume":"172","author":"L Klotz","year":"2004","unstructured":"Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172:S48\u2013S51","journal-title":"J Urol"},{"key":"1144_CR32","doi-asserted-by":"crossref","unstructured":"Studer UE et al. (2004) Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08\/88. J Clin Oncol 22(20):4109\u20134118","DOI":"10.1200\/JCO.2004.11.514"},{"key":"1144_CR33","doi-asserted-by":"crossref","unstructured":"Nair B, Wilt T, MacDonald R, et al. (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD003506"},{"key":"1144_CR34","first-page":"165","volume":"7","author":"DP Byar","year":"1988","unstructured":"Byar DP, Corle DK (1988) Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7:165\u2013170","journal-title":"NCI Monogr"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-013-1144-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-013-1144-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-013-1144-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T14:01:36Z","timestamp":1563631296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-013-1144-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s00345-013-1144-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}